Navigation Links
Lilly Comments on Court Ruling in Amylin Litigation

INDIANAPOLIS, May 25, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today commented on a ruling issued by the U.S. District Court for the Southern District of California granting a request by Amylin Pharmaceuticals for a temporary restraining order (TRO) related to litigation involving the two companies' diabetes collaboration agreement.  

"We are disappointed with the Court's decision to grant a temporary restraining order in this case," said Robert A. Armitage, senior vice president and general counsel for Lilly. "We have complied with our contractual obligations under our agreements with Amylin in a manner fully consistent with all applicable laws.  We believe that Amylin's allegations against Lilly are entirely without merit and we fully expect to prevail in this litigation."

Enrique Conterno, president of Lilly Diabetes, said, "The focus of our business remains on the patients we serve. We seek to offer a broad range of treatment options, including important new therapies, to people with diabetes and their health care providers."

Lilly is taking the appropriate steps to comply with the Court's order, including as it relates to the activities of its sales force, while working to mitigate the impact of any temporary modifications to its diabetes business.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.  Additional information about Lilly is available at  C-LLY

This press release contains forward-looking statements about our alliance with Amylin, and it reflects Lilly's current beliefs. There are substantial risks and uncertainties in the process of drug development and commercialization. Further, we cannot predict the outcome of any litigation with Amylin or its effect on our collaboration. For further discussion of risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.


SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement
2. Study Determined Best Dose and Showed 55 Percent Response Rate With Lilly Anti-BAFF Monoclonal Antibody in Previously-Treated Multiple Myeloma Patients
3. David M. Kendall, M.D., Named Distinguished Medical Fellow at Lilly
4. Lilly Provides Its Perspective in Response to Amylin Lawsuit
5. Lilly Provides Statement in Response to Amylin Lawsuit
6. Lilly USA, LLC Launches TruAssist for Patients
7. Lilly Oncology to Unveil Data From More Than 30 Studies at ASCO
8. Lilly Oncology to Present New Data on Nine of Its Pipeline Molecules at ASCO 2011
9. Amylin Pharmaceuticals Files Suit Against Eli Lilly
10. Eli Lilly and Company Invests $2.5 Million to Launch The Mind Trusts Grow What Works Campaign
11. U.S. District Court Order Maintains Patent Exclusivity for Lillys Cymbalta
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology:
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
Breaking Medicine News(10 mins):